SEARCH

Search Details

KAWAMOTO Shinichiro
University Hospital / Department of Diagnostic Pathology
Associate Professor

Researcher basic information

■ Research Areas
  • Life sciences / Hematology and oncology

Research activity information

■ Paper
  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Kazuhiko Doi, Hironori Sakai, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami
    Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen-specific antibody sequence (QASAS) method to assess the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the coronavirus antibody database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines. We analyzed repeated blood samples of healthy volunteers before and after monovalent XBB.1.5 vaccination (BNT162b2 XBB.1.5 or mRNA-1273.815) for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.
    Aug. 2024, EJHaem, 5(4) (4), 661 - 668, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Ryosuke Kuroda, Takahiro Niikura, Tomoyuki Matsumoto, Tomoaki Fukui, Keisuke Oe, Yutaka Mifune, Hironobu Minami, Hiroshi Matsuoka, Kimikazu Yakushijin, Yoshiharu Miyata, Shinichiro Kawamoto, Tatsuo Kagimura, Yasuyuki Fujita, Atsuhiko Kawamoto
    BACKGROUND: We previously demonstrated that CD34 + cell transplantation in animals healed intractable fractures via osteogenesis and vasculogenesis; we also demonstrated the safety and efficacy of this cell therapy in an earlier phase I/II clinical trial conducted on seven patients with fracture nonunion. Herein, we present the results of a phase III clinical trial conducted to confirm the results of the previous phase studies using a larger cohort of patients. METHODS: CD34 + cells were mobilized via administration of granulocyte colony-stimulating factor, harvested using leukapheresis, and isolated using magnetic cell sorting. Autologous CD34 + cells were transplanted in 15 patients with tibia nonunion and 10 patients with femur nonunion, who were followed up for 52 weeks post transplantation. The main outcome was a reduction in time to heal the tibia in nonunion patients compared with that in historical control patients. We calculated the required number of patients as 15 based on the results of the phase I/II study. An independent data monitoring committee performed the radiographic assessments. Adverse events and medical device failures were recorded. RESULTS: All fractures healed during the study period. The time to radiological fracture healing was 2.8 times shorter in patients with CD34 + cell transplantation than in the historical control group (hazard ratio: 2.81 and 95% confidence interval 1.16-6.85); moreover, no safety concerns were observed. CONCLUSIONS: Our findings strongly suggest that autologous CD34 + cell transplantation is a novel treatment option for fracture nonunion. TRIAL REGISTRATION: UMIN-CTR, UMIN000022814. Registered on 22 June 2016.
    Oct. 2023, BMC medicine, 21(1) (1), 386 - 386, English, International magazine
    Scientific journal

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Wataru Hojo, Hironori Sakai, Sakuya Matsumoto, Marika Watanabe, Akihito Kitao, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami
    The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.
    Jun. 2023, British journal of haematology, 202(3) (3), 504 - 516, English, International magazine
    Scientific journal

  • Hiroya Ichikawa, Kimikazu Yakushijin, Yoshiharu Miyata, Hirofumi Kanehira, Miki Joyce, Yuri Hirakawa, Sakuya Matsumoto, Shigeki Nagao, Rina Sakai, Keiji Kurata, Akihito Kitao, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
    Abstract Sinusoidal obstruction syndrome (SOS) is a fatal complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis for SOS can improve clinical outcomes significantly. Here, we performed a retrospective study to investigate the Cairo diagnostic criteria, in which SOS was defined as the development of two or more in seven events, including transfusion‐refractory thrombocytopenia. Among 154 cases of allogeneic HSCT, 10 cases of SOS using the European Society for Blood and Marrow Transplantation criteria (EBMT16) as the reference standard were identified. The original Cairo criteria could diagnose SOS 5 days earlier than any other established criteria, with some false‐positive results (sensitivity = 100.0%; specificity = 72.2%). When the cutoff was set to three events for the Cairo criteria, the diagnosis of SOS could be made 3 days earlier than that using the EBMT16 criteria, with comparable precision (specificity = 86.1%). The accuracy of the Cairo criteria improved further when the cutoff point was set to four (specificity = 93.8%). The fulfillment of the Cairo criteria was associated with high mortality. Based on our results, the Cairo criteria were also considered clinically useful, especially at three or four cutoff points. Further studies are required to validate and refine the criteria.
    Wiley, Jun. 2023, eJHaem
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Aki Inase, Yimamu Maimaitili, Shiro Kimbara, Yu Mizutani, Yoshiharu Miyata, Shinya Ohata, Hisayuki Matsumoto, Akihito Kitao, Rina Sakai, Koji Kawaguchi, Ako Higashime, Shigeki Nagao, Keiji Kurata, Hideaki Goto, Shinichiro Kawamoto, Kimikazu Yakushijin, Hironobu Minami, Hiroshi Matsuoka
    In acute myeloid leukemia (AML), the heterogeneity of genetic and epigenetic characteristics makes treatment difficult. The prognosis for AML is therefore poor, and there is an urgent need for new treatments for this condition. Gemtuzumab ozogamicin (GO), the first antibody-drug conjugate (ADC), targets the CD33 antigen expressed in over 90% of AML cases. GO therefore has the potential to counter the heterogeneity of AML patients. However, a major clinical problem is that drug resistance to GO diminishes its effect over time. Here, we report that the inhibition of glycogen synthase kinase 3 (GSK3) alone overcomes several forms of GO resistance at concentrations without antileukemic effects. The GSK3 inhibitors tested significantly enhanced the cytotoxic effect of GO in AML cell lines. We elucidated four mechanisms of enhancement: (1) increased expression of CD33, the target antigen of GO; (2) activation of a lysosomal function essential for hydrolysis of the GO linker; (3) reduced expression of MDR1 that eliminates calicheamicin, the payload of GO; and (4) reduced expression of the anti-apoptotic factor Bcl-2. A similar combination effect was observed against patient-derived primary AML cells. Combining GO with GSK3 inhibitors may be efficacious in treating heterogeneous AML.
    Feb. 2023, EJHaem, 4(1) (1), 153 - 164, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Efficacy and Safety of Synbiotics in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Randomized, Double-blinded, Placebo-controlled Pilot Study
    Yu Mizutani, Shinichiro Kawamoto, Michiko Takahashi, Hisayo Doi, Kumiko Wakida, Satoko Tabuchi, Masaaki Tanda, Akihiro Soga, Ruri Chijiki, Hidetomo Takakura, Koji Kawaguchi, Ako Higashime, Marika Watanabe, Hiroya Ichikawa, Sakuya Matsumoto, Rina Sakai, Hideaki Goto, Keiji Kurata, Seiji Kakiuchi, Yoshiharu Miyata, Kiyoaki Uryu, Yumiko Inui, Akihito Kitao, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    Corresponding, Feb. 2023, Internal Medicine, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Hiroya Ichikawa, Hironori Sakai, Wataru Hojo, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
    We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23-71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.
    Oct. 2022, Vaccines, 10(11) (11), English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yoriko Matsuyama, Hiroki Hosoi, Ryosuke Horitani, Shinichiro Kawamoto, Tadayuki Hashimoto, Masatomo Kimura, Hiroaki Nakai, Toshiki Mushino, Takashi Sonoki
    Springer Science and Business Media LLC, Jun. 2022, Ann Hematol ., 101(6) (6), 1343 - 1344
    [Refereed]
    Scientific journal

  • Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Koyama T, Imamura Y, Kiyota N, Matsuoka H, Mori Y, Minami H
    Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.
    Jun. 2022, Vaccines (Basel), 10(6) (6), 965, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Biclonal diffuse large B-cell lymphoma commonly characterized by partial trisomy 18q involving MALT1 and BCL2
    Yamamoto K, Kawamoto S, Chijiki R, Watanabe M, Matsumoto S, Kitao A, Mizutani Y, Kajimoto K, Hayashi Y, Yakushijin K, Minami H
    Jun. 2022, Internal Medicine
    [Refereed]
    Link to Kobe Univ. Repository (Kernel)

  • 当院における骨髄増殖性腫瘍のJAK2 V617F変異アレルバーデンの解析
    梅本遥菜, 野口依子, 松井啓治, 松本久幸, 今西孝充, 三枝 淳, 神保直江, 河野誠司, 川本 晋一郎
    Last, Feb. 2022, 日本検査血液学会雑誌, 23(1) (1), 19 - 27, Japanese
    [Refereed]
    Scientific journal

  • Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Wataru Hojo, Sakai R, Nagao S, Kitao A, Miyata Y, Koyama T, Saito Y, Kawamoto S, Ito M, Murayama T, Matsuoka H, Minami H
    Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.
    Jan. 2022, Vaccines (Basel), 10(2) (2), 158, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, Saeki M, Hirakawa Y, Sakai R, Matsumoto S, Mizutani Y, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Nishimura M, Imamura Y, Kiyota N, Matsuoka H, Mori Y, Minami H
    We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.
    Jan. 2022, International journal of Hematology, 115(1) (1), 7 - 10, English, Domestic magazine
    [Refereed]
    Scientific journal

  • AIHA診療における最近の動向
    川本 晋一郎
    Jan. 2022, 血液内科, 84(1) (1), 6 - 11, Japanese
    [Invited]
    In book

  • Hemolytic anemia
    Shinichiro Kawamoto
    Nov. 2021, Pharma Medica, 39(11) (11), 15 - 17, Japanese
    [Invited]
    In book

  • Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases
    Ohji G, Funakoshi Y, Ebisawa K, Yakushijin K, Arakawa Y, Saegusa J, Kawamoto S, Imanishi T, Mori Y, Iwata K, Minami H
    Oct. 2021, Kobe Journal of Medical Science, 67(2) (2), E55 - E60
    [Refereed]
    Link to Kobe Univ. Repository (Kernel)

  • 慢性GVHDに対する肝移植後の一過性末梢血マクロキメリズム(Transient macrochimerism following a liver transplant for hepatic GVHD after an allo-PBSCT)
    渡部 まりか, 藥師神 公和, 蔵満 薫, 福本 巧, 林 宏樹, 安冨 栄一郎, 千々木 瑠里, 高倉 嗣丈, 坂井 里奈, 松本 咲耶, 長尾 茂輝, 水谷 優, 宮田 吉晴, 北尾 章人, 川本 晋一郎, 山本 克也, 松岡 広, 南 博信
    (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, PS - 6, English

  • 自家造血幹細胞移植患者におけるsynbiotics投与の有効性についての臨床試験(Efficacy of synbiotics in auto-PBSCT patients: a prospective, double-blind, placebo-controlled trial)
    水谷 優, 川本 晋一郎, 丹田 雅明, 曽我 昭宏, 脇田 久美子, 田渕 聡子, 高橋 路子, 土井 久容, 千々木 瑠里, 高倉 嗣丈, 川口 晃司, 東目 亜湖, 渡部 まりか, 市川 大哉, 松本 咲耶, 坂井 里奈, 後藤 秀彰, 倉田 啓史, 垣内 誠司, 宮田 吉晴, 瓜生 恭章, 乾 由美子, 北尾 章人, 藥師神 公和, 松岡 広, 南 博信
    (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, OS2 - 4, English

  • 同種移植におけるflash sensor-based glucose monitoringの安全性の検討(Safety and accuracy of flash sensor-based glucose monitoring devise in patients after Allo-HSCT)
    長尾 茂輝, 藥師神 公和, 東目 亜湖, 川口 晃司, 渡部 まりか, 坂井 里奈, 水谷 優, 垣内 誠司, 倉田 啓史, 北尾 章人, 宮田 吉晴, 今村 善宣, 廣田 勇士, 高橋 路子, 川本 晋一郎, 山本 克也, 松岡 広, 南 博信
    (一社)日本血液学会, Sep. 2021, 日本血液学会学術集会, 83回, OS3 - 5, English

  • 自己免疫性溶血性貧血
    川本 晋一郎
    Oct. 2020, 生体の科学, 71(5) (5), 458 - 459, Japanese
    [Invited]

  • Diagnosis and treatment of autoimmune hemolytic anemia: the role of B-1 cells in secondary AIHA
    Shinichiro Kawamoto
    Sep. 2020, 臨床血液, 61(9) (9), 1089 - 1097, Japanese
    [Refereed][Invited]
    Scientific journal

  • Identification of the target molecule of autoantibodies in acquired autoimmune hemolytic anemia
    Shinichiro Kawamoto
    May 2020, 臨床血液, 61(5) (5), 491 - 501, Japanese
    [Refereed][Invited]
    Scientific journal

  • Akihito Kitao, Shinichiro Kawamoto, Keiji Kurata, Ikuyo Hayakawa, Takashi Yamasaki, Hiroshi Matsuoka, Yasuo Sumi, Yoshihiro Kakeji, Toyomi Kamesaki, Hironobu Minami
    Autoimmune hemolytic anemia (AIHA) is a rare comorbidity in colorectal cancer (CRC) and has an unknown etiology. Previously, we described an AIHA case secondary to CRC with ectopic band 3 expression. Herein, we investigated ectopic band 3 expression and erythrocyte membrane-bound IgG in a CRC cohort. Between September 2016 and August 2018, 50 patients with CRC and 26 healthy controls were enrolled in the present study. The expression of band 3 and SLC4A1 mRNA was observed in 97% of CRC surgical specimens. Although clinical AIHA was not observed in any patient with CRC, a direct antiglobulin test was positive in 10 of the patients in the CRC group (p = 0.01). Flow cytometry revealed significantly increased erythrocyte membrane-bound IgG among patients with CRC compared to healthy controls (mean ± standard deviation; 38.8 ± 4.7 vs. 29.9 ± 15.6, p = 0.012). Normocytic anemia was observed, including in cases negative for fecal occult blood, suggesting a shortened erythrocyte life-span due to increased membrane-bound IgG. Immunoprecipitation revealed increased anti-band 3 autoantibodies in patients' sera. Mouse experiments recapitulated this phenomenon. We also confirmed that band 3 expression is controlled by 5'AMP-activated protein kinase under hypoxic conditions. These findings increase our understanding of the etiology of cancer-related anemia.
    Corresponding, May 2020, International journal of hematology, 111(5) (5), 657 - 666, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Katsuya Yamamoto, Shinichiro Kawamoto, Akihito Kitao, Yu Mizutani, Yumiko Inui, Kimikazu Yakushijin, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    Springer Science and Business Media LLC, Jul. 2019, International Journal of Hematology, 110(1) (1), 107 - 114
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Okuni M, Yakushijin Kimikazu, Uehara Keiichiro, Ichikawa H, Suto H, Hashimoto A, Tanaka Y, Shinzato I, Sakai R, Mizutani Y, Nagao S, Kurata K, Kakiuchi S, Miyata Y, Inui Y, Saito Y, Kawamoto Shinichiro, Yamamoto K, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    A 45-year-old woman was diagnosed with hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma. She received different types of chemotherapy, but disease progression was observed. To reduce the tumor burden before an unrelated bone marrow transplantation, combination chemotherapy consisting of the gemcitabine, carboplatin, and dexamethasone (GCD) was administered as bridging therapy, resulting in a reduction in the number of lymphoma cells. We were then able to perform bone marrow transplantation. Although she experienced some adverse events, she successfully achieved long-term remission. We herein report a successful case of HSTCL treated with unrelated stem cell transplantation following the GCD regimen as bridging chemotherapy.
    Mar. 2019, Intern Med., 58(5) (5), 707 - 712, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Inui Y, Yakushijin Kimikazu, Okamura A, Tanaka Y, Shinzato I, Nomura T, Ichikawa H, Mizutani Y, Kitao A, Kurata K, Kakiuchi S, Miyata Y, Sanada Y, Kitagawa K, Uryu K, Kawamoto Shinichiro, Yamamoto K, Matsuoka Hiroshi, Murayama T, Ito Mitsuhiro, Minami Hironobu
    BACKGROUND: Human herpesvirus 6 (HHV-6) encephalitis is a known life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, few studies have focused on the occurrence of HHV-6 encephalitis in patients receiving mycophenolate mofetil (MMF) combined with a calcineurin inhibitor as prophylaxis for graft-versus-host disease (GVHD). This study aimed to investigate the impact of MMF administered for GVHD prophylaxis in the occurrence of HHV-6 encephalitis after allo-HSCT and the characteristics of this condition. METHODS AND RESULTS: We retrospectively analyzed 73 patients who underwent allo-HSCT (83 transplants) at our hospital between April 2010 and December 2015. MMF (2-3 g/d) was administered along with a calcineurin inhibitor. Seven patients (8.0%) developed encephalitis due to HHV-6. The median period from allo-HSCT to the onset of HHV-6 encephalitis was 23 days (range, 17-98 days). The cumulative incidence of HHV-6 encephalitis on day 100 after treatment was 12% and 6% in patients who underwent cord blood transplantation (CBT) and non-CBT (ie, bone marrow transplantation and peripheral blood stem cell transplantation), respectively (P = 0.344). Neurological symptoms of encephalitis were more severe in non-CBT cases than those in CBT cases. All patients diagnosed with HHV-6 encephalitis were treated with ganciclovir or foscarnet. None of the enrolled patients died from HHV-6 encephalitis. CONCLUSIONS: Mycophenolate mofetil may have the potential to increase the frequency of severe HHV-6 encephalitis in patients undergoing CBT and non-CBT. Thus, MMF should be administered with caution, and patients should be monitored closely for HHV-6 encephalitis even those who did not undergo CBT.
    Feb. 2019, Transpl Infect Dis., 21(1) (1), e13024, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kawamoto Shinichiro, Kamesaki T, Masutani R, Kitao A, Hatanaka K, Imakita M, Tamaki T, Takubo T
    Cancer patients occasionally have anemia with high mean corpuscular volume in addition to iron deficiency anemia. Secondary autoimmune hemolytic anemia (AIHA) following cancer is also observed with low frequency. To date, no causal mechanisms for these disease states have been reported. Here, we present the case of an 80-year-old woman with AIHA that was resistant to prednisolone. Further examinations revealed primary adenocarcinoma of the sigmoid colon and primary squamous cell carcinoma in the right lung. After resections of these tumors, her anemia partially improved until a colon cancer-derived metastatic tumor was detected in the left lung. Immunoprecipitation of erythrocyte membrane proteins with an autoantibody followed by mass spectrometry/Western blotting identified band 3 as the target of the autoantibody. Immunohistochemical analysis revealed ectopic expression of band 3 in the colon adenocarcinoma. To our knowledge, this is the first report that identifies the cause in a case of anemia without bleeding in a cancer patient and that defines a mechanism underlying secondary AIHA following cancer progression.
    Jan. 2019, Hum Pathol, 83, 193 - 198, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kurata K, Nishimura S, Ichikawa H, Sakai R, Mizutani Y, Takenaka K, Kakiuchi S, Miyata Y, Kitao A, Yakushijin Kimikazu, Kawamoto Shinichiro, Yamamoto K, Ito Mitsuhiro, Matsuoka Hiroshi, Tokimatsu I, Kamei K, Minami Hironobu
    Scopulariopsis alboflavescens is a soil saprophyte that is widely distributed in nature. Recently, there have been increasing number of reports of invasive infections with Scopulariopsis species in immunocompromised patients. In this report, we described an adult woman with acute myeloid leukemia and who developed S. alboflavescens pneumonia. Liposomal amphotericin B and voriconazole combination therapy was unsuccessful and the patient died because of pneumonia. Scopulariopsis is highly resistant to available antifungal agents and almost invariably fatal. This case report should alert clinicians to the importance of listing Scopulariopsis as a pathogenic fungus in immunocompromised patients.
    Dec. 2018, Int J Hematol., 108(6) (6), 658 - 664, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Toll-like receptor 4 promoter polymorphisms in a familial mediterranean fever patient with asymptomatic bacteriuria
    Kawamoto Shinichiro, Masutani R, Kurata K, Shima E, Iwatani Y, Takubo T
    Nov. 2018, Clin Case Rep, 7(1) (1), 155 - 159, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例(Aplastic anemia that developed asymptomatic CMV infection due to SNPs of TLR9)
    北尾 章人, 川本 晋一郎, 水谷 優, 坂井 里奈, 市川 大哉, 須藤 洋崇, 藥師神 公和, 松岡 広, 南 博信
    (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1756 - 1756, English

  • 新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7+CD56+急性骨髄性白血病(Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7+CD56+ AML with t(10;17)(p15;q21))
    山本 克也, 藥師神 公和, 市川 大哉, 垣内 誠司, 川本 晋一郎, 松本 久幸, 中町 祐司, 三枝 淳, 松岡 広, 南 博信
    (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1640 - 1640, English
    [Refereed]

  • Keiji Kurata, Kimikazu Yakushijin, Ishikazu Mizuno, Hiroshi Gomyo, Atsuo Okamura, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Yukinari Sanada, Yumiko Inui, Kiyoaki Uryu, Shinichiro Kawamoto, Takeshi Sugimoto, Katsuya Yamamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Tohru Murayama, Hironobu Minami
    Springer Science and Business Media LLC, Jul. 2018, International Journal of Hematology, 108(1) (1), 58 - 65
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Keiji Kurata, Kimikazu Yakushijin, Atsuo Okamura, Motohiro Yamamori, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Shinichiro Kawamoto, Hiroshi Matsuoka, Tohru Murayama, Hironobu Minami
    Springer Science and Business Media LLC, May 2018, Cancer Chemotherapy and Pharmacology, 81(5) (5), 839 - 846
    Scientific journal

  • Okuni M, Yakushijin K, Sakai Y, Suto H, Ichikawa H, Sakai R, Kakiuchi S, Kurata K, Mizutani Y, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Matsuoka H, Minami H
    Lymph node infarction is very rare, and is frequently associated with neoplasms, such as malignant lymphoma and non-neoplastic disease, or interventions such as fine-needle aspiration (FNA). A 76-year-old-man presented with cervical lymph node swelling. Although FNA was performed, the findings were insufficient for a definitive diagnosis. Consequently, surgical biopsy of the cervical lymph node was performed, which revealed total infarction; a diagnosis of classical Hodgkin lymphoma was made later. Both lymphoma itself and FNA may cause total lymph node infarction, which makes diagnosis confusing. Therefore, it is important to repeat the biopsy rather than repeat FNA to correctly diagnose malignant lymphoma, including Hodgkin lymphoma.
    Mar. 2018, Journal of clinical and experimental hematopathology : JCEH, 58(1) (1), 24 - 26, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • NagamataS, NagasakaM, KawabataA, KishimotoK, HasegawaD, KosakaY, Mori Takeshi, Morioka Ichiro, Nishimura Noriyuki, IijimaK, YamadaH, KawamotoS, Yakushijin Kimikazu, Matsuoka Hiroshi, MoriY
    Feb. 2018, J Clin Virol, 102, 50 - 55, English
    [Refereed]
    Scientific journal

  • 加古川中央市民病院で経験した cup-like 核形態を有する急性骨髄性白血病 4 症例の検討
    礒野雪妃, 岡村篤夫, 池田真穂, 中谷三穂, 今井純子, 増田由佳子, 池嶋由加里, 秋篠達也, 乾由美子, 白木里織, 岡村明治, 松本久幸, 中町祐司, 河野誠司, Kawamoto Shinichiro, 山崎家春, 西郷勝康, 巽英二
    2018, 臨 床 病 理, 66, 962 - 967, Japanese
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Yumiko Inui, Shinichiro Kawamoto, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    Springer Science and Business Media LLC, Dec. 2017, International Journal of Hematology, 106(6) (6), 729 - 731
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の1例
    毛利 華奈子, 坂井 里奈, 須藤 洋崇, 川本 晋一郎, 藥師神 公和, 松岡 広, 南 博信
    (一社)日本血液学会-東京事務局, Nov. 2017, 臨床血液, 58(11) (11), 2289 - 2289, Japanese

  • 悪性リンパ腫患者におけるコリンエステラーゼ値層別化による腫瘍崩壊症候群発症リスクの後方視的解析
    小嶋 真理子, 坂井 里奈, 川本 晋一郎, 市川 大哉, 水谷 優, 倉田 啓史, 垣内 誠司, 宮田 吉晴, 北尾 章人, 藥師神 公和, 山本 克也, 松岡 広, 南 博信
    (一社)日本血液学会-東京事務局, Sep. 2017, 臨床血液, 58(9) (9), 1763 - 1763, Japanese

  • Megumi Kishimoto, Masaya Akashi, Kazuyuki Tsuji, Junya Kusumoto, Shungo Furudoi, Yasuyuki Shibuya, Yumiko Inui, Kimikazu Yakushijin, Shinichiro Kawamoto, Atsuo Okamura, Hiroshi Matsuoka, Takahide Komori
    Jul. 2017, PLOS ONE, 12(7) (7), e0182021, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Seiji Kakiuchi, Yosuke Minami, Yoshiharu Miyata, Yu Mizutani, Hideaki Goto, Shinichiro Kawamoto, Kimikazu Yakushijin, Keiji Kurata, Hiroshi Matsuoka, Hironobu Minami
    MDPI AG, Feb. 2017, International Journal of Molecular Sciences, 18(3) (3), 486 - 486
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Shinichiro Kawamoto, Katsuya Yamamoto, Masanori Toyoda, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    Constitutional translocations that coincide with t(9;22)(q34;q11.2) may lead to unnecessary treatments in chronic myeloid leukemia (CML) patients, as, under the standard criteria, a diagnosis of CML with additional chromosomal abnormalities indicates an accelerated phase (AP). In the present report, a 47-year-old male had pain in the right foot due to gout. Peripheral blood examination showed leukocytosis with left shift. Bone marrow aspiration revealed myeloid hyperplasia with megakaryocytosis. RT-PCR revealed the major BCR-ABL fusion transcript, and CML in the chronic phase was diagnosed, followed by nilotinib treatment. Although WBC counts decreased immediately, G-banding analysis showed 46,XY,t(8;22)(q24;q11.2),t(9;22)(q34;q11.2) [20]. The t(8;22)(q24;q11.2) translocation is known to be recurrent in Burkitt's lymphoma. The diagnosis was changed to CML in AP, leading to B-lymphoid crisis. Unexpectedly, the karyotype was 46,XY,t(8;22)(q24;q11.2) [20] in hematological complete remission, even after 3 months. Fluorescence in situ hybridization on metaphase spreads revealed the MYC signal on the der(22)t(8;22), indicating that the 8q24 breakpoint was centromeric to MYC at 8q24.21. G-banding analysis of phytohemagglutinin-stimulated peripheral blood T-lymphocytes also indicated 46,XY,t(8;22)(q24.1;q11.2). We conclude that the t(8;22) is constitutional in this patient. As the tumor suppressor gene TRC8/RNF139 is disrupted by constitutional t(8;22)(q24.13;q11.21) in dysgerminoma, it may be associated with the onset of CML.
    Feb. 2017, International Journal of Hematology, 105(2) (2), 226 - 229, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • YAMAMOTO Katsuya, YAKUSHIJIN Kimikazu, KURATA Keiji, MIZUTANI Yu, INUI Yumiko, URYU Kiyoaki, KAWAMOTO Shinichiro, SUGIMOTO Takeshi, MATSUOKA Hiroshi, MINAMI Hironobu

    A 49-year-old female was initially diagnosed with acute myeloid leukemia (AML) M4 with a CD45＋CD13＋CD33＋CD34−HLA-DR＋ immunophenotype. She underwent allogeneic bone marrow transplantation, but the disease recurred. The bone marrow was infiltrated with 87.0% blasts negative for myeloperoxidase (MPO) staining. Immunophenotyping by flow cytometry identified the presence of a CD45-negative blast population. These blasts exhibited a CD13＋CD33＋CD19−CD10−CD34−HLA-DR− immunophenotype. The lack of CD45 expression is often observed in B-cell acute lymphoblastic leukemia, whereas CD45-negative AML is extremely rare; only one older male with AML-M0 has been reported. In the present case, the CD45-negative blasts had an MPO−CD13＋CD33＋ phenotype, which is similar to AML-M0.

    The Japanese Society of Hematology, 2017, Rinsho Ketsueki, 58(8) (8), 938 - 941, Japanese

  • Katsuya Yamamoto, Shinichiro Kawamoto, Keiji Kurata, Akihito Kitao, Yu Mizutani, Hiroya Ichikawa, Kimikazu Yakushijin, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    Oncogene amplification is uncommon in acute myeloid leukemia (AML). Cytogenetically, it is primarily found as double minute chromosomes (dmin) or homogeneously staining regions (hsr). A 62-year-old woman was admitted to our hospital because of anemia and thrombocytopenia. Her bone marrow was hypercellular with 78.6% myeloperoxidase- positive blasts. Some had micronuclei. The patient was diagnosed with AML M2 and remains in complete remission (CR) after induction therapy. G-banding at diagnosis showed 51,XX,t(11;16)(q13;p11.2),+r1,+mar1×4. Spectral karyotyping confirmed t(11;16) and revealed that the ring and the marker chromosomes were derived from multiple copies of ring chromosome 8. Fluorescence in situ hybridization (FISH) with a MYC probe at 8q24 detected amplified MYC signals on 1 large and 4 small ring chromosomes 8. One MYC signal was deleted from one of the 2 chromosomes 8. FISH with a FUS probe at 16p11.2 showed monoallelic deletion of FUS. Immunohistochemistry demonstrated MYC protein overexpression at diagnosis and almost negative expression in CR. These results indicate that MYC amplification could occur in ring chromosomes without dmin. A cryptic MYC deletion suggests that an episome model could be applicable to MYC amplification in ring chromosomes as observed for dmin and hsr. Furthermore, considering 2 further reported cases, t(11;16)(q13;p11) may be a very rare but recurrent translocation in AML.
    2017, Cytogenetic and genome research, 153(3) (3), 131 - 137, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen.
    Yoshiharu Miyata, Kimikazu Yakushijin, Yumiko Inui, Yoshinori Imamura, Hideaki Goto, Yu Mizutani, Keiji Kurata, Seiji Kakiuchi, Yukinari Sanada, Yosuke Minami, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Ryo Tominaga, Hiroshi Gomyo, Ishikazu Mizuno, Tetsuhiko Nomura, Koichi Kitagawa, Takeshi Sugimoto, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
    To identify strategies for reducing emesis induced by the CHOP regimen, which includes high-dose steroids, we prospectively evaluated the efficacy of palonosetron in Japanese patients. Palonosetron was administered at a dose of 0.75 mg via intravenous injection over 30 min before chemotherapy on day 1. Patients kept diaries of chemotherapy-induced nausea and vomiting (CINV) incidence from the start of chemotherapy until 168 h afterwards, in which they documented the occurrence and severity of nausea, vomiting, anorexia, and the use of rescue medication. The primary endpoint was the overall occurrence rate of nausea, vomiting, and anorexia; these rates were 56, 12, and 62 %, respectively, including all grades. The rates and severity of symptoms tended to worsen 120-168 h after completing oral prednisolone. We defined complete response (CR) as no vomiting and no use of rescue therapy. The CR rates of post palonosetron 0.75 mg treatment in the acute (0-24 h), delayed (24-168 h), and overall phases (0-168 h) were 86, 66, and 62 %, respectively. Antiemetic strategies of CHOP regimen for day 6 and, thereafter, should be investigated.
    Dec. 2016, International journal of hematology, 104(6) (6), 682 - 691, English, Domestic magazine
    Scientific journal

  • Sea-blue histiocytes in acute myeloid leukemia with trisomy 9.
    Katsuya Yamamoto, Yosuke Minami, Shinichiro Kawamoto, Kimikazu Yakushijin, Tomoe Kikuma, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami
    Nov. 2016, International journal of hematology, 104(5) (5), 531 - 533, English, Domestic magazine
    [Refereed]

  • Katsuya Yamamoto, Yosuke Minami, Kimikazu Yakushijin, Yu Mizutani, Yumiko Inui, Shinichiro Kawamoto, Keiji Matsui, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami
    2016, Cytogenetic and Genome Research, 150(3-4) (3-4), 287 - 292
    Scientific journal

  • Katsuya Yamamoto, Shinichiro Kawamoto, Yu Mizutani, Kinnikazu Yakushijin, Tonnoe Yamashita, Yuji Nakannachi, Seiji Kawano, Yoshitake Hayashi, Hiroshi Matsuoka, Hironobu Minami
    2016, CYTOGENETIC AND GENOME RESEARCH, 149(3) (3), 165 - 170, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Yosuke Minami, Kimikazu Yakushijin, Yu Mizutani, Yumiko Inui, Shinichiro Kawamoto, Keiji Matsui, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami
    2016, CYTOGENETIC AND GENOME RESEARCH, 150(3-4) (3-4), 287 - 292, English
    [Refereed]
    Scientific journal

  • 骨髄異形成症候群（MDS）における好中球の異形成と、多項目自動血球分析装置XE-2100の指標（NEUT-X, NEUT-Y）との関連
    礒野雪妃, 岡村篤夫, 岩本美佳, 今井純子, 長田恵子, 秋篠達也, 岡村明治, Kawamoto Shinichiro, 河野麻理, 杉本健, 西郷勝康
    日本臨床検査医学会 ; 1953-, Jan. 2016, 臨床病理, 64(1) (1), 21 - 26, Japanese
    [Refereed]
    Scientific journal

  • Yukinari Sanada, Kimikazu Yakushijin, Tetsuhiko Nomura, Naoko Chayahara, Masanori Toyoda, Yosuke Minami, Naomi Kiyota, Toru Mukohara, Shinichiro Kawamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
    Oxford University Press, 2016, Japanese Journal of Clinical Oncology, 46(5) (5), 448 - 452, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Keiji Kurata, Yukinari Sanada, Shinichiro Kawamoto, Hiroshi Matsuoka, Hironobu Minami
    Springer-Verlag Tokyo, May 2015, International Journal of Hematology, 101(5) (5), 423 - 425, English
    Research society

  • 造血幹細胞移植患者に対する栄養管理への介入とその評価
    生田智子, 丹田雅明, 青木紫織, 曽我昭宏, 山岡慶子, 田淵聡子, 高橋路子, Kawamoto Shinichiro, 薬師神公和, 西岡達也, 槇本博雄, 久米学, 平野剛, 宇佐美眞, 平井みどり
    Mar. 2015, 日本薬学会年会要旨集, (135年会4号) (135年会4号), 140, Japanese
    [Refereed]
    Scientific journal

  • K. Tsuji, Y. Shibuya, M. Akashi, S. Furudoi, K. Yakushijin, S. Kawamoto, A. Okamura, H. Matsuoka, T. Komori
    Feb. 2015, JOURNAL OF DENTAL RESEARCH, 94(2) (2), 289 - 296, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Shinichiro Kawamoto, Seiji Kakiuchi, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    2015, ACTA HAEMATOLOGICA, 134(2) (2), 76 - 79, English
    [Refereed]
    Scientific journal

  • Coexistent t(8;21)(q22;q22) Translocation and 5q Deletion in Acute Myeloid Leukemia
    YamamotoK, YakushijinK, SanadaY, Kawamoto Shinichiro, Matsuoka Hiroshi, MinamiH
    2015, J Clin Exp Hematop, 55(3) (3), 181 - 5, English
    [Refereed]
    Scientific journal

  • Katsuya Yamamoto, Kimikazu Yakushijin, Yukinari Sanada, Shinichiro Kawamoto, Yuji Nakamachi, Seiji Kawano, Hiroshi Matsuoka, Hironobu Minami
    Jan. 2015, ANNALS OF HEMATOLOGY, 94(1) (1), 177 - 179, English
    [Refereed]
    Scientific journal

  • 肺、大腸重複癌に合併した自己免疫性溶血性貧血における自己抗体の標的分子の同定
    Kawamoto Shinichiro, 宮田 吉晴, 桝谷 亮太, Matsuoka Hiroshi, 今北 正美, Minami Hironobu, 田窪 孝行, 玉置 俊治
    (一社)日本血液学会-東京事務局, Sep. 2014, 臨床血液, 55(9号) (9号), 1271 - 1271, Japanese
    Research society

  • A new complex translocation t(8;11;21)(q22;q24;q22) in acute myeloid leukemia with RUNX1/RUNX1T1
    Yamamoto K, Yakushijin Kimikazu, Funakoshi Y, Sanada Y, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    2014, J Clin Exp Hematop, 54(2) (2), 167 - 70, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Dasatinib Monotherapy to Maintain Complete Remission before Allogeneic Bone Marrow Transplantation under Monitoring of the Blastic Chronic Myelogenous Leukemia Biphenotypic Cells and Bcr-Abl Transcripts
    Kawamoto Shinichiro, Yonetani N, Masutani R, Ikemoto T, Takubo T
    2013, Prensa Med, 99(10) (10), English
    [Refereed]
    Scientific journal

  • Shinichiro Kawamoto, Kazuo Hatanaka, Masami Imakita, Toshiharu Tamaki
    2013, INTERNAL MEDICINE, 52(10) (10), 1107 - 1110, English
    [Refereed]
    Scientific journal

■ MISC
  • Katsuya Yamamoto, Kimikazu Yakushijin, Hiroya Ichikawa, Atsuo Okamura, Shigeki Nagao, Seiji Kakiuchi, Keiji Kurata, Shinichiro Kawamoto, Keiji Matsui, Yuji Nakamachi, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami
    May 2019, Leukemia & lymphoma, 60(5) (5), 1294 - 1298, English, International magazine
    [Refereed]
    Report scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Katsuya Yamamoto, Kimikazu Yakushijin, Hiroya Ichikawa, Seiji Kakiuchi, Shinichiro Kawamoto, Hisayuki Matsumoto, Yuji Nakamachi, Jun Saegusa, Hiroshi Matsuoka, Hironobu Minami
    Nov. 2018, Leukemia & lymphoma, 59(11) (11), 2706 - 2710, English, International magazine
    [Refereed]
    Report scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 自家末梢血幹細胞移植における栄養状態と予後に関する後方視的解析
    水谷優, 藥師神公和, 市川大哉, 坂井里奈, 後藤秀彰, 倉田啓史, 西村明子, 北尾章人, 田渕聡子, 瓜生恭章, 垣内誠司, 宮田吉晴, 乾由美子, 眞田幸尚, 今村善宣, 船越洋平, 高橋路子, 高橋路子, 岡村篤夫, 川本晋一郎, 山本克也, 伊藤光宏, 松岡広, 南博信, 南博信
    2017, 日本造血細胞移植学会総会プログラム・抄録集, 40th

  • 30年来頸部腫瘤を有する患者より発症したDouble-hit lymphoma(DHL)の1例
    水谷優, Kawamoto Shinichiro, 後藤秀彰, 倉田啓史, 垣内誠司, 眞田幸尚, 宮田吉晴, 山本克也, Matsuoka Hiroshi, 南博信, 伊藤智雄
    (一社)日本血液学会-東京事務局, Nov. 2015, 臨床血液, 56(11号) (11号), 2377 - 2377, Japanese
    [Refereed]
    Meeting report

  • 化学療法中の固形腫瘍患者に対するインフルエンザワクチン2回接種法の有効性と安全性
    眞田幸尚, 藥師神公和, 野村哲彦, Chayahara Naoko, 豊田昌彦, 清田尚臣, Kawamoto Shinichiro, 向原徹, Matsuoka Hiroshi, 南博信
    Feb. 2015, 日本内科学会雑誌, 104(Suppl.) (Suppl.), 241, Japanese
    [Refereed]
    Meeting report

  • Seiji Kakiuchi, Kimikazu Yakushijin, Katsuya Yamamoto, Hideo Tomioka, Yumiko Inui, Atsuo Okamura, Shinichiro Kawamoto, Yosuke Minami, Tohru Murayama, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
    2015, INTERNAL MEDICINE, 54(16) (16), 2057 - 2060, English
    [Refereed]
    Report scientific journal

  • Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study
    Yukinari Sanada, Kimikazu Yakushijin, Tetsuhiko Nomura, Katsuya Yamamoto, Keiji Kurata, Kei Takenaka, Seiji Kakiuchi, Yoshiharu Miyata, Yoshinori Imamura, Meiko Nishimura, Yohei Funakoshi, Yuriko Iwamoto, Naoko Chayahara, Masanori Toyoda, Yosuke Minami, Naomi Kiyota, Toru Mukohara, Shinichiro Kawamoto, Yohei Shimono, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
    Dec. 2014, BLOOD, 124(21) (21), English
    Summary international conference

  • 腹部DLBCL病変出現1ヵ月前に発症したNeurolymphomatosisの1例
    井本 寛東, Kawamoto Shinichiro, 垣内 誠司, 宮田 吉晴, 眞田 幸尚, 川森 有里子, Yakushijin Kimikazu, 南 陽介, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本血液学会-東京事務局, Nov. 2014, 臨床血液, 55(11号) (11号), 2339 - 2339, Japanese
    Meeting report

  • チロシンキナーゼ型受容体C-KIT変異による標的遺伝子制御機構の解析
    川本 晋一郎, 桝谷 亮太, 田窪 孝行
    (一社)日本血液学会-東京事務局, Sep. 2013, 臨床血液, 54(9) (9), 1203 - 1203, Japanese

  • 白血病幹細胞樹立の試み
    桝谷 亮太, 川本 晋一郎, 池本 敏行, 田中 秀麿, 村上 澄子, 田窪 孝行
    (一社)日本検査血液学会, Jun. 2012, 日本検査血液学会雑誌, 13(学術集会) (学術集会), S144 - S144, Japanese

  • Outcomes of reduced-intensity stem-cell transplantation (RIST) in patients with hematologic diseases
    HATANAKA KAZUO, KAWAMOTO SHIN-ICHIRO, TAMAKI TOSHIHARU
    日本無菌生物ノートバイオロジー学会, 01 Dec. 2005, Journal of germfree life and gnotobiology, 35(2) (2), 122 - 125, Japanese

  • New Quinolone Versus Vancomycin/Tobramycin for Intestinal Sterilization in Patients Who Undergo Allogeneic Bone Marrow Transplants
    HOSEN Naoki, TESHIMA Hirofumi, KARASUNO Takahiro, UJIIE Hidetoshi, NAKAO Takafumi, YAGI Toshiya, HATANAKA Kazuo, KAWAMOTO Shin-ichiro, HIRAOKA Akira, NAKAMURA Hiroyuki, MASAOKA Toru
    日本臨床血液学会, 30 Jan. 1999, 臨床血液, 40(1) (1), 9 - 15, Japanese

■ Lectures, oral presentations, etc.
  • Nutrition and Rehabilitation of Hematopoietic Stem Cell Transplantation Patients
    Hisayo Doi, Aya Okano, Mika Tanaka, Michiko Takahashi, Satoko Tabuchi, Junichiro Inoue, Keiji Kurata, Shinichiro Kawamoto, Hiroshi Matsuoka, Kimikazu Yakushijin
    APBMT, Nov. 2018, English, アジア太平洋骨髄移植学会, Taipei, International conference
    Poster presentation

  • 新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7+CD56+急性骨髄性白血病
    山本 克也, YAKUSHIJIN KIMIKAZU, 市川 大哉, 垣内 誠司, KAWAMOTO SHINICHIRO, 松本 久幸, 中町 祐司, 三枝 淳, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例.
    北尾 章人, KAWAMOTO SHINICHIRO, 水谷 優, 坂井 里奈, 市川 大哉, 須藤 洋崇, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第80回日本血液学会学術集会, Oct. 2018, Japanese, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • Aplastic anemia that developed asymptomatic CMV infection due to a single nucleotide polymorphism of TLR9
    Akihito Kitao, Shinichiro Kawamoto, Yu Mizutani, Rina Sakai, Hiroya Ichikawa, Hirotaka Suto, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
    第80回日本血液学会学術集会, Oct. 2018, English, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • Flow cytometric measurement of erythrocyte membrane-bound IgG: A potential diagnostic method for colorectal cancer
    北尾 章人, KAWAMOTO SHINICHIRO, 倉田 啓史, 早川 郁代, MATSUOKA HIROSHI, 角 泰雄, 掛地 吉弘, 亀崎 豊美, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Flow cytometric measurement of erythrocyte membrane-bound IgG: A potential diagnostic method for colorectal cancer
    Akihito Kitao, Shinichiro Kawamoto, Keiji Kurata, Ikuyo Hayakawa, Hiroshi Matsuoka, Yasuo Sumi, Yoshihiro Kakeji, Toyomi Kamesaki, Hironobu Minami
    Aemrican Association for Cancer Research Annual Meeting 2018, Apr. 2018, English, American Association for Cancer Research, シカゴ, International conference
    Poster presentation

  • 非血縁者間骨髄移植前の病勢コントロールとしてGCD療法が有効であった肝脾原発T細胞性リンパ腫の一例
    大國まりか, 市川大哉, 須藤洋崇, 橋本朗子, 田中康博, 新里偉咲, 長尾茂樹, 坂井里奈, 水谷優, 北尾章人, 倉田啓史, 垣内誠司, 宮田吉晴, 乾由美子, 齊藤 泰之, Yakushijin Kimikazu, Kawamoto Shinichiro, Ito Mitsuhiro, 山本克也, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Poster presentation

  • Investigation of patients who required intensive care during the course of allo-HSCT
    北尾章人, Yakushijin Kimikazu, Misumi Takuyo, 東目亜湖, 川口晃司, 坂井里奈, 市川大哉, 水谷優, 倉田啓史, 長尾茂輝, 垣内誠司, 宮田吉晴, Kawamoto Shinichiro, 岡村篤夫, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Oral presentation

  • A retrospective analysis of Pharmaceutical Inquiries in the Transplantation Unit
    丸上奈穂, 奥野護, 丹田雅明, 宮田吉晴, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Oral presentation

  • 自家末梢血幹細胞移植における栄養状態と予後に関する方視的解析
    水谷 優, Yakushijin Kimikazu, 市川 大哉, 坂井 里奈, 後藤 秀彰, 倉田 啓史, 西村 明子, 北尾 章人, 田渕 聡子, 瓜生 恭章, 垣内 誠司, 宮田 吉晴, 乾 由美子, 眞田 幸尚, Takahashi Michiko, 岡村 篤夫, Kawamoto Shinichiro, 山本 克也, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Poster presentation

  • 血縁ドナーにおける血液成分分離装置Spectra OptiaとCOBE Spectraの採取データの比較検討
    宮田 吉晴, Kawamoto Shinichiro, 市川大哉, 坂井里奈, 水谷優, 倉田啓史, 垣内誠司, 北尾章人, 真田幸尚, 乾由美子, Yakushijin Kimikazu, 岡村篤夫, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Poster presentation

  • Pharmacokinetics of intravenous mycophenolate mofetil after hematopoietic stem cell transplantation in Japanese population
    Keiji Kurata, Atsuo Okamura, Motohiro Yamamori, Yakushijin Kimikazu, Koji Kawaguchi, Ako Higashime, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    ASBMT/CIBMTR tandem meetings 2018, Feb. 2018, English, ASBMT/CIBMTR, Salt Lake City, USA, International conference
    Poster presentation

  • Pharmacokinetics of intravenous mycophenolate mofetil after cord blood transplantation in Japanese
    Keiji Kurata, Atsuo Okamura, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Akihito Kitao, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第40回日本造血細胞移植学会総会, Feb. 2018, Japanese, 日本造血細胞移植学会, 札幌, Domestic conference
    Oral presentation

  • 悪性リンパ腫との鑑別に難渋した多中心性細網組織球症（MRH）の1例
    塙 信人, 大川 智史, 岡田 志緒子, 藤森 明, 眞壁 郁, 山崎 隆, Kawamoto Shinichiro, Kanzawa Maki, 小柴 賢洋, 泉 美貴
    第218回近畿地方会, Dec. 2017, Japanese, 日本内科学会近畿支部, 神戸, Domestic conference
    Oral presentation

  • Retrospective analysis of TLS risk in lymphoma patients stratified by cholinesterase level
    Mariko Kojima, Risa Sakai, Kawamoto Shinichiro, Hiroya Ichikawa, Yu Mizutani, Keiji Kurata, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Yakushijin Kimikazu, Katsuya Yamamoto, Matsuoka Hiroshi, Minami Hironobu
    第79回日本血液学会学術集会, Oct. 2017, Japanese, 日本血液学会, 東京, Domestic conference
    Poster presentation

  • Retrospective analysis of the ESHAP regimen for malignant lymphoma in Kobe University Hospital.
    Miyata Y, Yakushijin Kimikazu, Ichikawa H, Sakai R, Goto H, Mizutani Y, Kurata K, Kakiuchi S, Kitao A, Kawamoto Shinichiro, Yamamoto K, Ito M, Matsuoka Hiroshi, Minami Hironobu
    第79回日本血液学会学術集会, Oct. 2017, English, 日本血液学会, 東京, Domestic conference
    Poster presentation

  • MYC amplification in the form of ring chromosomes 8 in acute myeloid leukemia with t(11;16)(q13;p11)
    Katsuya Yamamoto, Kawamoto Shinichiro, Keiji Kurata, Akihito Kitao, Yu Mizutani, Hiroya Ichikawa, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    The 79th annual meeting of the Japanese Society of Hematology, Oct. 2017, Japanese, Japanese Society of Hematology, 東京, Domestic conference
    Poster presentation

  • c-Kit遺伝子変異細胞株においてmicroRNA-7はRB1発現を抑制し染色体不安定性をもたらす
    倉田 啓史, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第76回日本癌学会学術集会, Sep. 2017, Japanese, 日本癌学会, 神奈川（横浜）, Domestic conference
    Poster presentation

  • Establishment and Gene Expression Analysis of a Double-Hit Lymphoma Cell Line
    Keiji Kurata, Kawamoto Shinichiro, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Akihito Kitao, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の一例
    毛利華奈子, 坂井里奈, 須藤洋崇, Kawamoto Shinichiro, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu, 毛利華奈子
    第107回近畿血液学地方会, Jun. 2017, Japanese, 日本血液学会, 京都, Domestic conference
    Oral presentation

  • MicroRNA-7 suppresses RB1 expression leading to chromosomal instability in leukemia cells harboring c-Kit mutation
    Keiji Kurata, Kawamoto Shinichiro, Ryota Masutani, Yakushijin Kimikazu, Katsuya Yamamoto, Matsuoka Hiroshi, Takayuki Takubo, Minami Hironobu
    Annual Meeting of the American Association for Cancer Research 2017, Apr. 2017, English, American Asociation for Cancer Research, Washington DC, USA, International conference
    Poster presentation

  • A Case of Refractory Chronic GVHD of Lips Successfully Treated with Wrap Therapy
    市川 大哉, 奥野 真紀子, 坂井 里奈, 水谷 優, 倉田 啓史, 須藤 洋崇, 垣内 誠司, 北尾 章人, 宮田 吉晴, 眞田 幸尚, 乾 由美子, 瓜生 恭章, Saito Yasuyuki, Yakushijin Kimikazu, Kawamoto Shinichiro, 田村 恵利, 岸本 恵実, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    The 39th Annual Meeting of the Japan Socitey for Hematopoietic Cell Transplantation, Mar. 2017, Japanese, The Japan Society for Hematopoietic Cell Transplantation, 島根, Domestic conference
    Poster presentation

  • Effective immunosuppressive therapy with cyclosporine-A against relapsed pri mary cutaneous gamma/delta T-cell lymphoma after auto-PBSCT
    Kawamoto Shinichiro, 市川 大哉, 水谷 優, 北尾 章人, Yakushijin Kimikazu, 山本 克也, Matsuoka Hiroshi, Minami Hironobu
    第39回日本造血細胞移植学会総会, Mar. 2017, Japanese, 日本造血細胞移植学会, 松江, Domestic conference
    Poster presentation

  • The antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen
    宮田 吉晴, Yakushijin Kimikazu, 乾 由美子, 今村 善宣, 後藤 秀彰, 水谷 優, 倉田 啓史, 垣内 誠司, 眞田 幸尚, Minami Yosuke, Kawamoto Shinichiro, Ito Mitsuhiro, 富永 亮, 五明 広志, 水野 石一, 野村 哲彦, 喜多川 浩一, 杉本 健, 村山 徹, Matsuoka Hiroshi, Minami Hironobu
    The 78th Annual Meeting of the Japanese Society of Hematology, Oct. 2016, Japanese, The Japanese Society of Hematology, 横浜, Domestic conference
    Poster presentation

  • Constitutional t(8;22)(q24;11.2) that mimics variant Burkitt-type translocation in Ph positive CML
    横路 優子, Kawamoto Shinichiro, 山本 克也, 坂井 里奈, 水谷 優, 北尾 章人, Toyoda Masanori, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    The 78th Annual Meeting of the Japanese Society of Hematology, Oct. 2016, Japanese, The Japanese Society of Hematology, 横浜, Domestic conference
    Poster presentation

  • Mycophenolate mofetil for GVHD prophylaxis might not favor the development of engraftment syndrome.
    Ymiko Inui, Kmikazu Yakushijin, Hiroya Ichikawa, Yu Mizutani, Keiji Kurata, Akihito Kitao, Atsuo Okamura, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    The 78th annual meeting of the japanese society of hematology, Oct. 2016, Japanese, Japanese Society of Hematology, 横浜, Domestic conference
    Poster presentation

  • LONG-TERM FOLLOW-UP OUTPATIENT PROGRAM AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Hisayo Doi, Aya Okano, Mami Ishiyama, Masaaki Tanda, Junichiro Inoue, Keiji Kurata, Yoshiharu Miyata, Kawamoto Shinichiro, Yakushijin Kimikazu, Kayoko Ito
    21st Congress of APBMT, Oct. 2016, English, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, International conference
    Oral presentation

  • Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo AML with t(11;20)(p15;q12) and t(2;5)(q33;q31)
    Katsuya Yamamoto, Minami Yosuke, Yakushijin Kimikazu, Yu Mizutani, Yumiko Inui, Kawamoto Shinichiro, Keiji Matsui, Yuji Nakamachi, Seiji Kawamo, Matsuoka Hiroshi, Minami Hironobu
    第78回日本血液学会学術集会, Oct. 2016, Japanese, 日本血液学会, 横浜市, Domestic conference
    Poster presentation

  • BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia .
    Akihito Kitao, Yakushijin Kimikazu, Eriko Honda, Hiroya Ichikawa, Yu Mizutani, Yoshiharu Miyata, Kiyoaki Uryu, Yumiko Inui, Kawamoto Shinichiro, Matsuoka Hiroshi, Ito Mitsuhiro, Tomoo Ito, Minami Hironobu
    The 78th annual meeting of the japanese society of hematology, Oct. 2016, Japanese, Japanese Society of Hematology, 横浜, Domestic conference
    Poster presentation

  • A REDUCED INTENSITY CONDITIONING REGIMEN USING FLUDARABINE AND BUSULFAN (FLU-BU2)
    Keiji Kurata, Yakushijin Kimikazu, Hiroya Ichikawa, Rina Sakai, Hirotaka Suto, Yumiko Inui, Atsuo Okamura, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    The 21st Annual Congress of Asia Pacific Blood and Marrow Transplantation Group 2016, Oct. 2016, English, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, International conference
    Poster presentation

  • リンパ節生検で完全梗塞が認められ診断に難渋したホジキンリンパ腫の1例
    大國まりか, 須藤洋崇, 市川大哉, Yakushijin Kimikazu, 柳沢俊学, Sakai Yasuhiro, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第213回日本内科学会近畿地方会, Sep. 2016, Japanese, 日本内科学会, 大阪, Domestic conference
    Oral presentation

  • 発熱性好中球減少症における質量分析を用いた菌種同定の有用性についての検討
    水谷 優, Kawamoto Shinichiro, 市川 大哉, 西村 明子, 乾 由美子, 北尾 章人, Toyoda Masanori, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 同種造血幹細胞移植後のリンパ球回復と予後に関する後方視的解析
    倉田 啓史, Yakushijin Kimikazu, 乾 由美子, 岡村 篤夫, Kawamoto Shinichiro, Minami Yosuke, 山本 克也, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 造血器悪性腫瘍に対する化学療法中のD-indexと口腔内感染性合併症との関連についての検討
    Akashi Masaya, 岸本 恵実, 辻 和志, 楠元 順哉, Yakushijin Kimikazu, Kawamoto Shinichiro, 岡村 篤夫, Matsuoka Hiroshi, Furudoi Shungo, Komori Takahide
    第14回日本臨床腫瘍学会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸市, Domestic conference
    Oral presentation

  • 急性骨髄性白血病に対するヘッジホッグ阻害薬投与の治療反応性バイオマーカーとしてのNANOG発現
    垣内 誠司, Minami Yosuke, 福島 庸晃, 水谷 優, 倉田 啓史, Kawamoto Shinichiro, Yakushijin Kimikazu, 直江 知樹, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Treatment strategies for double primary neoplasm patients who develop malignant lymphoma and solid tumors
    北尾 章人, 水谷 優, 後藤 秀彰, 乾 由美子, Kawamoto Shinichiro, Yakushijin Kimikazu, Minami Yosuke, Matsuoka Hiroshi, Ito Mitsuhiro, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Quick detection of bacteria with mass spectrometry might reduce mortality in ferile neutropenia
    水谷 優, Kawamoto Shinichiro, 市川 大哉, 西村 明子, 乾 由美子, 北尾 章人, Toyoda Masanori, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Mycophenolate Mofetilを使用した造血幹細胞移植後に発症したHHV-6脳炎の治療経過
    乾 由美子, Yakushijin Kimikazu, 市川 大哉, 水谷 優, 北尾 章人, Kawamoto Shinichiro, 岡村 篤夫, 山本 克也, Matsuoka Hiroshi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Delayed Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation with Mycophenolate Mofetil
    Keiji Kurata, Yakushijin Kimikazu, Ishikazu Mizuno, Yumiko Inui, Hiroshi Gomyo, Atsuo Okamura, Ryo Tominaga, Kawamoto Shinichiro, Minami Yosuke, Akio Maeda, Katsuya Yamamoto, Tohru Murayama, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    7th, JSH International Symposium, May 2016, English, Japan Society of Hematology, Awaji, Japan, International conference
    Poster presentation

  • Absolute Lymphocyte Count Recovery Predicts Clinical Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in a Japanese Population
    Keiji Kurata, Yakushijin Kimikazu, Ishikazu Mizuno, Yumiko Inui, Hiroshi Gomyo, Atsuo Okamura, Hiroya Ichikawa, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Ryo Tominaga, Akihito Kitao, Yukinari Sanada, Saito Yasuyuki, Minami Yosuke, Kawamoto Shinichiro, Akio Maeda, Katsuya Yamamoto, Tohru Murayama, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    42nd, Annual Meeting of the European Society for Blood and Marrow Transplantation, Apr. 2016, English, European Society for Blood and Marrow Transplantation, Valencia, Spain, International conference
    Poster presentation

  • 自律神経ストームを伴った造血幹細胞移植後HHV-6脳炎
    乾 由美子, Yakushijin Kimikazu, 水谷 優, 市川 大哉, 倉田 啓史, 垣内 誠司, 宮田 吉晴, 眞田 幸尚, 北尾 章人, Minami Yosuke, Kawamoto Shinichiro, 田中 康博, 新里 偉咲, 山本 克也, 村山 徹, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    第38回日本造血幹細胞移植学会総会, Mar. 2016, Japanese, 日本造血細胞移植学会, 名古屋, Domestic conference
    Oral presentation

  • 造血幹細胞移植患者への栄養管理の前後比較
    田渕 聡子, Takahashi Michiko, 生田 智子, 曽我 明弘, 永濱 郁代, Yakushijin Kimikazu, Kawamoto Shinichiro, 筒井 輪央, 内田 絢子, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, 山本 将司, 戸田 明代, Usami Makoto
    第31回日本静脈経腸栄養学会学術集会, Feb. 2016, Japanese, 福岡, Domestic conference
    Oral presentation

  • 造血幹細胞移植患者への栄養管理の前後比較
    田渕 聡子, Takahashi Michiko, 生田 智子, 曽我 明弘, 永濱 郁代, Yakushijin Kimikazu, Kawamoto Shinichiro, 筒井 輪央, 内田 絢子, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, Yamamoto Masashi, 戸田 明代, Usami Makoto
    第19回日本病態栄養学会, Jan. 2016, Japanese, 日本静脈経腸栄養学会, 横浜, Domestic conference
    Oral presentation

  • 造血幹細胞移植患者へのNEST介入前後の栄養評価
    田渕 聡子, Takahashi Michiko, 生田 智子, 丹田 雅明, 青木 紫織, 奥野 護, 永濱 郁代, 土井 久容, Yakushijin Kimikazu, Kawamoto Shinichiro, 筒井 輪央, 内田 絢子, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, Yamamoto Masashi, 戸田 明代, Usami Makoto
    第31回日本静脈経腸栄養学会, Jan. 2016, Japanese, 日本静脈経腸栄養学会, 横浜, Domestic conference
    Oral presentation

  • 造血幹細胞移植患者へのNEST介入前後の栄養評価
    田渕 聡子, Takahashi Michiko, 生田 智子, 丹田 雅明, 青木 紫織, 奥野 護, 永濱 郁代, 土井 久容, Yakushijin Kimikazu, Kawamoto Shinichiro, 筒井 輪央, 内田 絢子, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, Yamamoto Masashi, 戸田 明代, Usami Makoto
    第19回日本病態栄養学会年次学術集会, Jan. 2016, Japanese, 日本病態栄養学会, 横浜, Domestic conference
    Oral presentation

  • 超高齢で発症した発作性夜間血色素尿症の1例。
    鷹津 英, 乾 由美子, 水谷 優, 能勢 拓, 倉田 啓史, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第210回日本内科学会近畿地方, Nov. 2015, Japanese, 日本内科学会, 神戸, Domestic conference
    Oral presentation

  • 診断に難渋したhairy cell leukemiaの一例。
    本多 瑛理子, 乾 由美子, 水谷 優, 北尾 章人, 瓜生 恭章, 市川 大哉, Yakushijin Kimikazu, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第210回日本内科学会近畿地方, Nov. 2015, Japanese, 日本内科学会, 神戸, Domestic conference
    Oral presentation

  • 30年来頚部腫瘤を有する患者より発症したDouble-hit lymphoma(DHL)の1例
    水谷 優, Kawamoto Shinichiro, 後藤 秀彰, 倉田 啓史, 垣内 誠司, 眞田 幸尚, 宮田 吉晴, 山本 克也, Matsuoka Hiroshi, Minami Hironobu
    第210回日本内科学会近畿地方, Nov. 2015, Japanese, 日本内科学会, 神戸, Domestic conference
    Oral presentation

  • Mixed phenotype acute leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and der(1;18)(q10;q10)
    山本 克也, Kawamoto Shinichiro, 水谷 優, Yakushijin Kimikazu, 倉田 啓史, 乾 由美子, 眞田 幸尚, 垣内 誠司, 宮田 吉晴, 山下 智江, 中町 祐司, Kawano Seiji, Matsuoka Hiroshi, Minami Hironobu
    第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference
    Poster presentation

  • Herpesvirus 6 Encephalitis after Hematopoietic Stem Cell Transplantation with Administration of Mycophenolate Mofetil for Graft-versus-host Disease Prophylaxis in Japan: a Single Institution Experience.
    Yumiko Inui, Yakushijin Kimikazu, Yu Mizutani, Keiji Kurata, Yoshiharu Miyata, Yukinari Sanada, Kawamoto Shinichiro, Atsuo Okamura, Matsuoka Hiroshi, Minami Hironobu
    第20回アジア太平洋造血細胞移植学会年次学術集会, Oct. 2015, English, アジア太平洋造血細胞移植学会, 沖縄, International conference
    Poster presentation

  • A case of scopulariopsis pneumonia with acute myeloid leukemia
    Kim S, Kurata K, Yokoro Y, Goto H, Mizutani Y, Takenaka K, Otera Hiroshi, Kawamoto Shinichiro, Yakushijin Kimikazu, Yamamoto Koji, Ito T, Matsuoka Hiroshi, Minami Hironobu
    第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference
    Poster presentation

  • A case of myeloid sarcoma with myelofibrosis secondary to polycthemia vera
    Ohmiya S, Kurata K, Nose T, Kawamoto Teruya, Kawamoto Shinichiro, Yakushijin Kimikazu, Yamamoto Koji, Ito T, Matsuoka Hiroshi, Minami Hironobu
    第77回日本血液学会学術集会, Oct. 2015, English, 日本血液学会, 金沢, Domestic conference
    Poster presentation

  • 血球貪食症候群を合併した脾臓原発びまん性大細胞型B細胞リンパ腫(DLBCL)の1例
    草野俊亮, 北尾章人, 田中健雄, Kenzaka Tsuneaki, Kawamoto Shinichiro, 市川大哉, 倉田啓史, Matsuoka Hiroshi, Minami Hironobu, 秋田穂束
    第209回日本内科学会近畿地方会, Sep. 2015, Japanese, 日本内科学会, 大阪, Domestic conference
    Oral presentation

  • 造血幹細胞移植患者へのNST介入の評価
    田渕 聡子, Takahashi Michiko, 生田 智子, 曽我 明弘, 永濱 郁代, Yakushijin Kimikazu, Kawamoto Shinichiro, 山西 美沙, 脇田 久美子, 三ヶ尻 礼子, 山本 育子, 山本 将司, 戸田 明代, Usami Makoto
    第7回日本静脈経腸栄養学会近畿支部学術集会, Jul. 2015, Japanese, 京都, Domestic conference
    Oral presentation

  • Absolute Lymphocyte Count Recovery Predicts Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
    Keiji Kurata, Yakushijin Kimikazu, Atsuo Okamura, Yukinari Sanada, Hideaki Goto, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Yumiko Inui, Yohei Funakoshi, Kiyoaki Uryu, Kawamoto Shinichiro, Minami Yosuke, Katsuya Yamamoto, Tohru Murayama, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    the 6th JSH International Symposium, May 2015, English, 日本血液学会, 軽井沢, Domestic conference
    Poster presentation

  • 化学療法中の固形腫瘍患者に対するインフルエンザワクチン2回接種法の有効性と安全性.
    眞田 幸尚, Yakushijin Kimikazu, 野村 哲彦, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Kawamoto Shinichiro, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第112回日本内科学会総会, Apr. 2015, Japanese, 日本内科学会, 京都, Domestic conference
    Oral presentation

  • 造血幹細胞移植患者に対する栄養管理への介入とその評価
    生田 智子, 丹田 雅明, 曽我 昭宏, 山岡 慶子, 青木 紫織, 田淵 聡子, Takahashi Michiko, 西岡 達也, 槇本 博雄, 久米 学, Hirano Takeshi, Kawamoto Shinichiro, Yakushijin Kimikazu, Usami Makoto, 平井 みどり
    日本薬学会第135年会, Mar. 2015, Japanese, 日本薬学会, 神戸, Domestic conference
    Poster presentation

  • 骨髄非破壊的造血幹細胞移植後の非感染性心内膜炎
    眞田 幸尚, Yakushijin Kimikazu, 垣内 誠司, 宮田 吉晴, 船越 洋平, Minami Yosuke, Kawamoto Shinichiro, 山本 克也, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
    第38回日本造血幹細胞移植学会総会, Mar. 2015, Japanese, 日本造血細胞移植学会, 名古屋, Domestic conference
    Oral presentation

  • Nonbacterial thrombotic endocarditis after reduced-intensity conditioning for stem cell transplantation
    眞田 幸尚, Yakushijin Kimikazu, 垣内 誠司, 宮田 吉晴, 船越 洋平, Minami Yosuke, Kawamoto Shinichiro, 山本 克也, 伊藤 光宏, Matsuoka Hiroshi, Minami Hironobu
    The 37th Annual Meeting of the Japan Society for Hematoloietic Cell Transplantation, Mar. 2015, English, 日本造血細胞移植学会, 神戸, Domestic conference
    Oral presentation

  • 急性骨髄性白血病に対して同種骨髄移植後にCandida Parapsilosis による横紋筋融解症を呈した1例
    垣内 誠司, Yakushijin Kimikazu, 山本 克也, 乾 由美子, 岡村 篤夫, Kawamoto Shinichiro, Minami Yosuke, 村山 徹, 伊藤 光宏, Matsuoka Hiroshi, Minami Hironobu
    第54回 神戸血液病研究会, Feb. 2015, Japanese, 神戸血液病研究会, 神戸, Domestic conference
    Oral presentation

  • Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study.
    Yukinari Sanada, Yakushijin Kimikazu, Tetsuhiko Nomura, Katsuya Yamamoto, Keiji Kurata, Kei Takenaka, Seiji Kakiuchi, Yoshiharu Miyata, Yoshinori Imamura, Meiko Nishimura, Yohei Funakoshi, Yuriko Iwamoto, Chayahara Naoko, Toyoda Masanori, Minami Yosuke, Kiyota Naomi, Mukohara Toru, Kawamoto Shinichiro, Shimono Yohei, Mitsuhiro Ito, Matsuoka Hiroshi, Minami Hironobu
    56th Meeting of the American Society of Hematology, Dec. 2014, English, American Society of Hematology, サンフランシスコ, International conference
    Poster presentation

  • 肺、大腸重複癌に合併した自己免疫性溶血性貧血における自己抗体の標的分子の同定
    Kawamoto Shinichiro, 宮田 吉晴, 桝谷 亮太, Matsuoka Hiroshi, 今北 正美, Minami Hironobu, 田窪 孝行, 玉置 俊治
    第76回日本血液学会学術集会, Oct. 2014, Japanese, 日本血液学会, 大阪, Domestic conference
    Oral presentation

  • MYC amplification in the form of double minute chromosomes in two cases of acute myeloid leukemia.
    Yamamaoto K, Yakushijin Kimikazu, Okamura A, Sanada Y, Kakiuchi S, Miyata Y, Iwamoto Y, Kawamoto Shinichiro, Matsuoka Hiroshi, Minami Hironobu
    第76回日本血液学会学術集会, Oct. 2014, English, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • A case of spontaneous hemophilia B diagnoses in adulthood
    Miyata Y, Higasa S, Kakiuchi S, Sanada Y, Iwamoto Y, Kawamoto Shinichiro, Yakushijin Kimikazu, Yamamaoto K, Murayama T, Kuroki Y, Matsuoka Hiroshi, Minami Hironobu
    第76回日本血液学会学術集会, Oct. 2014, English, 日本血液学会, 大阪, Domestic conference
    Poster presentation

■ Research Themes
TOP